GCN2 is required to increase fibroblast growth factor 21 and maintain hepatic triglyceride homeostasis during asparaginase treatment

American Journal of Physiology - Endocrinology and Metabolism

Volumn 308, Issue 4, 2015, Pages E283-E293

  Wilson, Gabriel J ^a   Lennox, Brittany A ^a   She, Pengxiang ^a   Mirek, Emily T ^a   Al Baghdadi, Rana J T ^a   Fusakio, Michael E ^d   Dixon, Joseph L ^a,b   Henderson, Gregory C ^a   Wek, Ronald C ^d   Anthony, Tracy G ^a,b,c  

^a RUTGERS UNIVERSITY   (United States)

^b the State University of New Jersey   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adipose; Amino acid response; Antithrombin III; Apolipoprotein B 100; Eukaryotic initiation factor 2; Fibroblast growth factor 21; General control nonderepressible 2; Liver; Mice; Oxidative stress; Steatosis

Indexed keywords

ANTITHROMBIN III; APOLIPOPROTEIN B100; ASPARAGINASE; FAS ANTIGEN; FIBROBLAST GROWTH FACTOR 21; GENERAL CONTROL NONDEREPRESSIBLE 2 PROTEIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATE BUFFERED SALINE; PROTEIN KINASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; EIF2AK4 PROTEIN, MOUSE; ESCHERICHIA COLI PROTEIN; FIBROBLAST GROWTH FACTOR; PROTEIN SERINE THREONINE KINASE;

AMINO ACID RESPONSE GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE; GENE EXPRESSION; LIPID HOMEOSTASIS; LIPID LIVER LEVEL; LIPID METABOLISM; LIPID PEROXIDATION; LIPOGENESIS; LIVER DYSFUNCTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WHITE ADIPOSE TISSUE; AGONISTS; ANIMAL; BLOOD; C57BL MOUSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HOMEOSTASIS; INTRAPERITONEAL DRUG ADMINISTRATION; KNOCKOUT MOUSE; LIVER; METABOLISM; PATHOLOGY; TOXIC HEPATITIS;

ADIPOSE TISSUE, WHITE; ANIMALS; ANTINEOPLASTIC AGENTS; ASPARAGINASE; BIOMARKERS; DRUG-INDUCED LIVER INJURY; ESCHERICHIA COLI PROTEINS; FEMALE; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; HOMEOSTASIS; INJECTIONS, INTRAPERITONEAL; LIPID PEROXIDATION; LIVER; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTEIN-SERINE-THREONINE KINASES; RNA, MESSENGER; TRIGLYCERIDES;

EID: 84922918736     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00361.2014     Document Type: Article

References (53)

1. Ai D, Baez JM, Jiang H, Conlon DM, Hernandez-Ono A, Frank-Kamenetsky M, Milstein S, Fitzgerald K, Murphy AJ, Woo CW, Strong A, Ginsberg HN, Tabas I, Rader DJ, Tall AR. Activation of ER stress and mTORC1 suppresses hepatic sortilin-1 levels in obese mice. J Clin Invest 122: 1677–1687, 2012.
2. Anthony TG, McDaniel BJ, Byerley RL, McGrath BC, Cavener DR, McNurlan MA, Wek RC. Preservation of liver protein synthesis during dietary leucine deprivation occurs at the expense of skeletal muscle mass in mice deleted for eIF2 kinase GCN2. J Biol Chem 279: 36553–36561, 2004.
3. Arriazu E, Perez de Obanos MP, Lopez-Zabalza MJ, Herraiz MT, Iraburu MJ. Amino acid deprivation decreases intracellular levels of reactive oxygen species in hepatic stellate cells. Cell Physiol Biochem 26: 281–290, 2010.
4. B’Chir W, Maurin AC, Carraro V, Averous J, Jousse C, Muranishi Y, Parry L, Stepien G, Fafournoux P, Bruhat A. The eIF2alpha/ATF4 pathway is essential for stress-induced autophagy gene expression. Nucleic Acids Res 41: 7683–7699, 2013.
5. Back SH, Scheuner D, Han J, Song B, Ribick M, Wang J, Gildersleeve RD, Pennathur S, Kaufman RJ. Translation attenuation through eIF2alpha phosphorylation prevents oxidative stress and maintains the differentiated state in beta cells. Cell Metab 10: 13–26, 2009.
6. Baird TD, Wek RC. Eukaryotic initiation factor 2 phosphorylation and translational control in metabolism. Adv Nutr 3: 307–321, 2012.
7. Balasubramanian MN, Butterworth EA, Kilberg MS. Asparagine syn-thetase: regulation by cell stress and involvement in tumor biology. Am J Physiol Endocrinol Metab 304: E789–E799, 2013.
8. Beeck H, Nagel D, Pindur G, Scharrer I, Preiss A, Seiler D, Hellstern P. Measurement of antithrombin activity by thrombin-based and by factor Xa-based chromogenic substrate assays. Blood Coagul Fibrinolysis 11: 127–135, 2000.
9. Ben Tanfous M, Sharif-Askari B, Ceppi F, Laaribi H, Gagne V, Rousseau J, Labuda M, Silverman LB, Sallan SE, Neuberg D, Kutok JL, Sinnett D, Laverdiere C, Krajinovic M. Polymorphisms of aspara-ginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia. Clin Cancer Res 2014 Jun 6 [Epub ahead of print].
10. Bi L, Chiang JY, Ding WX, Dunn W, Roberts B, Li T. Saturated fatty acids activate ERK signaling to downregulate hepatic sortilin 1 in obese and diabetic mice. J Lipid Res 54: 2754–2762, 2013.
11. Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krahen-buhl S. Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase. Digestion 74: 28–32, 2006.
12. Bunpo P, Cundiff JK, Reinert RB, Wek RC, Aldrich CJ, Anthony TG. The eIF2 kinase GCN2 is essential for the murine immune system to adapt to amino acid deprivation by asparaginase. J Nutr 140: 2020–2027, 2010.
13. Bunpo P, Dudley A, Cundiff JK, Cavener DR, Wek RC, Anthony TG. GCN2 protein kinase is required to activate amino acid deprivation responses in mice treated with the anti-cancer agent L-asparaginase. J Biol Chem 284: 32742–32749, 2009.
14. Cairo MS. Adverse reactions of L-asparaginase. Am J Pediatr Hematol Oncol 4: 335–339, 1982.
15. Castilho BA, Shanmugam R, Silva RC, Ramesh R, Himme BM, Sattlegger E. Keeping the eIF2 alpha kinase Gcn2 in check. Biochim Biophys Acta 1843: 1948–1968, 2014.
16. Chau MD, Gao J, Yang Q, Wu Z, Gromada J. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc Natl Acad Sci USA 107: 12553–12558, 2010.
17. Chaveroux C, Lambert-Langlais S, Parry L, Carraro V, Jousse C, Maurin AC, Bruhat A, Marceau G, Sapin V, Averous J, Fafournoux P. Identification of GCN2 as new redox regulator for oxidative stress prevention in vivo. Biochem Biophys Res Commun 415: 120–124, 2011.
18. Dang Do AN, Kimball SR, Cavener DR, Jefferson LS. eIF2alpha kinases GCN2 and PERK modulate transcription and translation of distinct sets of mRNAs in mouse liver. Physiol Genomics 38: 328–341, 2009.
19. De Sousa-Coelho AL, Marrero PF, Haro D. Activating transcription factor 4-dependent induction of FGF21 during amino acid deprivation. Biochem J 443: 165–171, 2012.
20. Durden DL, Salazar AM, Distasio JA. Kinetic analysis of hepatotoxicity associated with antineoplastic asparaginases. Cancer Res 43: 1602–1605, 1983.
21. Earl M. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol 7: 600–606, 2009.
22. Fisher EA, Pan M, Chen X, Wu X, Wang H, Jamil H, Sparks JD, Williams KJ. The triple threat to nascent apolipoprotein B. Evidence for multiple, distinct degradative pathways. J Biol Chem 276: 27855–27863, 2001.
23. Gross MA, Speer RJ, Hill JM. Hepatic lipidosis associated with L-as-paraginase treatment. Proc Soc Exp Biol Med 130: 733–736, 1969.
24. Guo F, Cavener DR. The GCN2 eIF2alpha kinase regulates fatty-acid homeostasis in the liver during deprivation of an essential amino acid. Cell Metab 5: 1–12, 2007.
25. Hao S, Sharp JW, Ross-Inta CM, McDaniel BJ, Anthony TG, Wek RC, Cavener DR, McGrath BC, Rudell JB, Koehnle TJ, Gietzen DW. Uncharged tRNA and sensing of amino acid deficiency in mammalian piriform cortex. Science 307: 1776–1778, 2005.
26. Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M, Ron D. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell 6: 1099–1108, 2000.
27. Harding HP, Zhang Y, Zeng H, Novoa I, Lu PD, Calfon M, Sadri N, Yun C, Popko B, Paules R, Stojdl DF, Bell JC, Hettmann T, Leiden JM, Ron D. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell 11: 619–633, 2003.
28. Henderson GC. Kinetic measurement techniques in the evaluation of lipid metabolism. Curr Drug Discov Technol 10: 209–223, 2013.
29. Hernandez-Espinosa D, Minano A, Martinez C, Perez-Ceballos E, Heras I, Fuster JL, Vicente V, Corral J. L-asparaginase-induced anti-thrombin type I deficiency: implications for conformational diseases. Am J Pathol 169: 142–153, 2006.
30. Hill JM, Roberts J, Loeb E, Khan A, MacLellan A, Hill RW. L-as-paraginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia. JAMA 202: 882–888, 1967.
31. Jiang HY, Wek SA, McGrath BC, Scheuner D, Kaufman RJ, Cavener DR, Wek RC. Phosphorylation of the alpha subunit of eukaryotic initiation factor 2 is required for activation of NF-kappaB in response to diverse cellular stresses. Mol Cell Biol 23: 5651–5663, 2003.
32. Jiang S, Yan C, Fang QC, Shao ML, Zhang YL, Liu Y, Deng YP, Shan B, Liu JQ, Li HT, Yang L, Zhou J, Dai Z, Jia WP. Fibroblast growth factor 21 is regulated by the IRE1alpha-XBP1 branch of the unfolded protein response and counteracts endoplasmic reticulum stress-induced hepatic steatosis. J Biol Chem 289: 29751–29765, 2014.
33. Kilberg MS, Balasubramanian M, Fu L, Shan J. The transcription factor network associated with the amino acid response in mammalian cells. Adv Nutr 3: 295–306, 2012.
34. Laeger T, Henagan TM, Albarado DC, Redman LM, Bray GA, Noland RC, Munzberg H, Hutson SM, Gettys TW, Schwartz MW, Morrison CD. FGF21 is an endocrine signal of protein restriction. J Clin Invest 124: 3913–3922, 2014.
35. Markan KR, Naber MC, Ameka MK, Anderegg MD, Mangelsdorf DJ, Kliewer SA, Mohammadi M, Potthoff MJ. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes 63: 4057–4063, 2014.
36. Muller G. [Acquired antithrombin III deficiency]. Z Gesamte Inn Med 47: 74–77, 1992.
37. Ollenschlager G, Roth E, Linkesch W, Jansen S, Simmel A, Modder B. Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects. Eur J Clin Invest 18: 512–516, 1988.
38. Pan M, Cederbaum AI, Zhang YL, Ginsberg HN, Williams KJ, Fisher EA. Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J Clin Invest 113: 1277–1287, 2004.
39. Panosyan EH, Grigoryan RS, Avramis IA, Seibel NL, Gaynon PS, Siegel SE, Fingert HJ, Avramis VI. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). Anticancer Res 24: 1121–1125, 2004.
40. Pereira IV, Stefano JT, Oliveira CP. Microsomal triglyceride transfer protein and nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 5: 245–251, 2011.
41. Qiu H, Dong J, Hu C, Francklyn CS, Hinnebusch AG. The tRNA-binding moiety in GCN2 contains a dimerization domain that interacts with the kinase domain and is required for tRNA binding and kinase activation. EMBO J 20: 1425–1438, 2001.
42. Raetz EA, Salzer WL. Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 32: 554–563, 2010.
43. Reinert RB, Oberle LM, Wek SA, Bunpo P, Wang XP, Mileva I, Goodwin LO, Aldrich CJ, Durden DL, McNurlan MA, Wek RC, Anthony TG. Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase. J Biol Chem 281: 31222– 31233, 2006.
44. Rousseau J, Gagne V, Labuda M, Beaubois C, Sinnett D, Laverdiere C, Moghrabi A, Sallan SE, Silverman LB, Neuberg D, Kutok JL, Krajinovic M. ATF5 polymorphisms influence ATF function and re sponse to treatment in children with childhood acute lymphoblastic leu kemia. Blood 118: 5883–5890, 2011.
45. Sahoo S, Hart J. Histopathological features of L-asparaginase-induced liver disease. Semin Liver Dis 23: 295–299, 2003.
46. Strong A, Ding Q, Edmondson AC, Millar JS, Sachs KV, Li X, Kumaravel A, Wang MY, Ai D, Guo L, Alexander ET, Nguyen D, Lund-Katz S, Phillips MC, Morales CR, Tall AR, Kathiresan S, Fisher EA, Musunuru K, Rader DJ. Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. J Clin Invest 122: 2807–2816, 2012.
47. Teske BF, Wek SA, Bunpo P, Cundiff JK, McClintick JN, Anthony TG, Wek RC. The eIF2 kinase PERK and the integrated stress response facilitate activation of ATF6 during endoplasmic reticulum stress. Mol Biol Cell 22: 4390–4405, 2011.
48. Vattem KM, Wek RC. Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells. Proc Natl Acad Sci USA 101: 11269–11274, 2004.
49. Wan XS, Lu XH, Xiao YC, Lin Y, Zhu H, Ding T, Yang Y, Huang Y, Zhang Y, Liu YL, Xu ZM, Xiao J, Li XK. ATF4- and CHOP-dependent induction of FGF21 through endoplasmic reticulum stress. Biomed Res Intl 2014: 807874, 2014.
50. Wilson GJ, Bunpo P, Cundiff JK, Wek RC, Anthony TG. The eukary-otic initiation factor 2 kinase GCN2 protects against hepatotoxicity during asparaginase treatment. Am J Physiol Endocrinol Metab 305: E1124–E1133, 2013.
51. Woo YC, Xu A, Wang Y, Lam KS. Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin Endocrinol 78: 489–496, 2013.
52. Xu X, Hu J, McGrath BC, Cavener DR. GCN2 in the brain programs PPARgamma2 and triglyceride storage in the liver during perinatal development in response to maternal dietary fat. PLoS One 8: e75917, 2013.
53. Zhou D, Palam LR, Jiang L, Narasimhan J, Staschke KA, Wek RC. Phosphorylation of eIF2 directs ATF5 translational control in response to diverse stress conditions. J Biol Chem 283: 7064–7073, 2008.